So Yeon Kim, MD, PhD; Jihyun An, MD; Young-Suk Lim, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(4):456-463. doi:10.1001/jamaoncol.2016.3147
This clinical trial examines the hepatocellular carcinoma detection rate using ultrasonography compared with magnetic resonance imaging in patients with cirrhosis who are at high risk for hepatocellular carcinoma.
Rachel Pearlman, MS, CGC; Wendy L. Frankel, MD; Benjamin Swanson, MD; et al.
free access
JAMA Oncol. 2017;3(4):464-471. doi:10.1001/jamaoncol.2016.5194
This cohort study examines the frequency and spectrum of cancer susceptibility gene mutations among patients with early-onset colorectal cancer.
-
Editorial
Universal Genetic Testing for Younger Patients With Colorectal Cancer
Eduardo Vilar, MD, PhD; Elena M. Stoffel, MD, MPH
JAMA Oncol
Frank A. Sinicrope, MD; Qian Shi, PhD; Carmen J. Allegra, MD; et al.
free access
JAMA Oncol. 2017;3(4):472-480. doi:10.1001/jamaoncol.2016.5469
This secondary analysis of 2 randomized clinical trials examines the association of DNA mismatch repair status and somatic gene mutations in the primary tumor of patients with stage III colon cancer treated with adjuvant chemotherapy.
Joanne B. Weidhaas, MD, PhD; Jonathan Harris, MS; Dörthe Schaue, PhD; et al.
free access
JAMA Oncol. 2017;3(4):483-491. doi:10.1001/jamaoncol.2016.5478
This secondary analysis of a randomized clinical trial examines whether a germline mutation in a microRNA-binding site in KRAS is a predictive biomarker of cetuximab response and altered immunity following radiotherapy and cisplatin treatment for head and neck squamous cell cancer.
Neil Mehta, MD; Julie Heimbach, MD; Denise M. Harnois, DO; et al.
free access
JAMA Oncol. 2017;3(4):493-500. doi:10.1001/jamaoncol.2016.5116
This multicenter study evaluated patients with hepatocellular carcinoma who underwent liver transplantation to develop and validate a recurrence prediction index.
Geert A. Cirkel, MD; Paul Hamberg, MD, PhD; Stefan Sleijfer, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(4):501-508. doi:10.1001/jamaoncol.2016.5202
This randomized clinical trial compares the effects of an 8-week rotating treatment schedule with pazopanib and everolimus vs continuous pazopanibon disease progression in patients with metastatic clear cell renal cell cancer.
Reva K. Basho, MD; Michael Gilcrease, MD, PhD; Rashmi K. Murthy, MD; et al.
free access
JAMA Oncol. 2017;3(4):509-515. doi:10.1001/jamaoncol.2016.5281
This cohort study investigates whether PI3K pathway鈥揹irected therapy is effective in the treatment of mesenchymal triple-negative breast cancer.
Vincent Chung, MD; Shannon McDonough, MS; Philip A. Philip, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(4):516-522. doi:10.1001/jamaoncol.2016.5383
This phase 2 randomized clinical trial compares selumetinib and MK-2206 vs modified FOLFOX chemotherapy in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed.